July 2019
Policy brief
HIV Treatment
Anema et al. AIDS Research and Therapy 2011, 8:13 http://www.aidsrestherapy.com/content/8/1/13
DHS Working Papers No. 110 | Zimbabwe Working Papers No. 11
Technical Update
HIV Treatment
July 2017
Acute Radiation Syndrome (ARS) (sometimes known as radiation
toxicity or radiation sickness) is an acute illness caused by
irradiation of the entire body (or most of the body) by a high dose
of penetrating radiation in a very short period of time (usually ... a
matter of minutes). The major cause of this syndrome is depletion
of immature parenchymal stem cells in specific tissues. Examples of
people who suffered from ARS are the survivors of the Hiroshima
and Nagasaki atomic bombs, the firefighters that first responded
after the Chernobyl Nuclear Power Plant event in 1986, and some
unintentional exposures to sterilization irradiators.
more
Настоящее руководство «Клиническое ведение случаев COVID-19» базируется на
вышеуказанных стратегических приоритетах и адресовано клиницистам, участвующим в
оказа...ии помощи пациентам с подозреваемой или подтвержденной инфекцией COVID-19.
Оно не предназначено для того, чтобы заменить индивидуальное клиническое суждение или
консультацию специалиста, но призвано помочь клиническим работникам в обеспечении
наиболее эффективного ведения случаев. Повышенное внимание в настоящем руководстве
уделяется вопросам, касающимся особых и уязвимых групп населения, таких как дети,
пожилые люди и беременные женщины.
Interim guidance on clinical management COVID-19
more
Desde hace muchas décadas, los microbios, en particular las bacterias, se han vuelto cada vez más resistentes a diversos antimicrobianos. El aval de la Asamblea Mundial de la Salud al Plan de Acción Mundial sobre la resistencia a los antimicrobianos, en mayo de 2015, y la Declaración política d...e la reunión de alto nivel de la Asamblea General sobre la resistencia a los antimicrobianos, en septiembre de 2016, reconocen que la resistencia a los antimicrobianos es una amenaza para la salud pública mundial. Estas iniciativas políticas reconocen el uso excesivo e inapropiado de los antimicrobianos como el principal factor que favorece dicha resistencia, así
como la necesidad de optimizar el uso de estos medicamentos.
more
Las personas infectadas por el virus de la inmunodeficiencia humana (VIH) tienen
29 veces más probabilidades de enfermar de tuberculosis (TB) que las personas
sin VIH que viven en el mismo país. La TB es una de las principales causas de muerte entre las personas infectadas por el VIH: provoca ...la quinta parte de las muertes de personas con VIH en todo el mundo. En 2013, una de cada cuatro muertes por TB en todo el mundo estuvo relacionada con el VIH. Desde 2004, la Organización Mundial de la Salud (OMS) recomienda el conjunto de intervenciones denominadas «actividades de colaboración TB/VIH». Se han realizado avances significativos en la aplicación a nivel mundial de este conjunto de intervenciones, que permitieron salvar aproximadamente 1,3 millones de vidas entre 2005 y 2011.
more
Update, 23 de junio de 2022
Mettre fin au choléra- Feuille de route mondiale pour 2030 rend opérationnelle la nouvelle stratégie mondiale de lutte contre le choléra au niveau des pays et fournit une voie concrète vers un monde où le choléra ne représente plus une menace pour la santé publique. En mettant en œuvre la ...stratégie d’ici à 2030, les partenaires du Groupe spécial mondial de lutte contre le choléra (GTFCC) aideront les pays à réduire de 90 % les décès dus au choléra. Avec l’engagement des pays touchés par le choléra, des partenaires techniques et des donateurs, pas moins de 20 pays pourraient éliminer la transmission de la maladie d’ici 2030.
more
This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are responding to the World Health Organization (WHO) call t...o action by putting into place best-practice TFA policies. Mandatory TFA policies are currently in effect for 3.4 billion people in 60 countries (43% of the world population); of these, 43 countries have best-practice policies in effect, covering 2.8 billion people (36% of the world population).
Over the past year, several additional countries took action to eliminate industrially produced TFA: best-practice policies came into effect in India in January 2022, Uruguay in May 2022 and Oman in July 2022. Best-practice policies were passed in Bangladesh in November 2021 (to come into effect in December 2022) and in Ukraine in September 2020 (to come into effect in October 2023), best-practice TFA policies are projected to pass soon in Mexico, Nigeria and Sri Lanka.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are responding to the World Health Organization (WHO) call t...o action by putting into place best-practice TFA policies. Mandatory TFA policies are currently in effect for 3.4 billion people in 60 countries (43% of the world population); of these, 43 countries have best-practice policies in effect, covering 2.8 billion people (36% of the world population).
Over the past year, several additional countries took action to eliminate industrially produced TFA: best-practice policies came into effect in India in January 2022, Uruguay in May 2022 and Oman in July 2022. Best-practice policies were passed in Bangladesh in November 2021 (to come into effect in December 2022) and in Ukraine in September 2020 (to come into effect in October 2023), best-practice TFA policies are projected to pass soon in Mexico, Nigeria and Sri Lanka.
more
The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist i...n various combinations in different individuals, to date there is limited evidence on how to integrate these for optimal monitoring of children with asthma. The aims of this ERS Task Force were to describe the current practise and give an overview of the best available evidence on how to monitor children with asthma.
22 clinical and research experts reviewed the literature. A modified Delphi method and four Task Force meetings were used to reach a consensus.
This statement summarises the literature on monitoring children with asthma. Available tools for monitoring children with asthma, such as clinical tools, lung function, bronchial responsiveness and inflammatory markers, are described as are the ways in which they may be used in children with asthma. Management-related issues, comorbidities and environmental factors are summarised.
Despite considerable interest in monitoring asthma in children, for many aspects of monitoring asthma in children there is a substantial lack of evidence.
more